

Yves Fradet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6023387/publications.pdf>

Version: 2024-02-01

38
papers

3,763
citations

430442

18
h-index

344852

36
g-index

39
all docs

39
docs citations

39
times ranked

6256
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 21.	0.8	2
2	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. <i>Clinical Nutrition ESPEN</i> , 2022, 47, 221-226.	0.5	2
3	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	3.2	21
4	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. <i>World Journal of Urology</i> , 2021, 39, 1549-1558.	1.2	9
5	Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. <i>Molecular Cancer Research</i> , 2021, 19, 516-527.	1.5	10
6	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. <i>Journal of Biomedical Optics</i> , 2021, 26, .	1.4	4
7	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , 2020, 17, e1003281.	3.9	19
8	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. <i>Canadian Urological Association Journal</i> , 2020, 14, 319-321.	0.3	11
9	Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer?. <i>Bladder Cancer</i> , 2020, 6, 63-69.	0.2	5
10	Assembling a network to promote translational bladder cancer research in Canada. <i>Canadian Urological Association Journal</i> , 2020, 14, E475-E481.	0.3	1
11	Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. <i>Prostate</i> , 2019, 79, 9-20.	1.2	28
12	Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. <i>Prostate</i> , 2019, 79, 1767-1776.	1.2	51
13	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1122-e1128.	0.9	9
14	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. <i>Radiation Oncology</i> , 2019, 14, 60.	1.2	18
15	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. <i>European Urology Focus</i> , 2019, 5, 998-1006.	1.6	25
16	Discordance between testosterone measurement methods in castrated prostate cancer patients. <i>Endocrine Connections</i> , 2019, 8, 132-140.	0.8	6
17	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1579-1587.	0.8	97
18	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 230-238.	0.3	51

#	ARTICLE	IF	CITATIONS
19	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5305-5312.	3.2	13
20	Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 363.e7-363.e11.	0.8	16
21	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	13.9	2,677
22	Metabolic Imaging of Prostate Cancer Reveals Inpatient Intermetastasis Response Heterogeneity to Systemic Therapy. <i>European Urology Focus</i> , 2017, 3, 639-642.	1.6	15
23	Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. <i>Nutrition and Cancer</i> , 2017, 69, 1196-1204.	0.9	10
24	Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. <i>Canadian Urological Association Journal</i> , 2017, 11, 419-24.	0.3	5
25	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. <i>European Urology</i> , 2016, 69, 601-609.	0.9	36
26	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. <i>Cancer Research</i> , 2015, 75, 950-962.	0.4	150
27	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. <i>Cancer Imaging</i> , 2015, 15, 2.	1.2	47
28	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. <i>Research and Reports in Urology</i> , 2014, 6, 27.	0.6	26
29	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
30	Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise. <i>Canadian Urological Association Journal</i> , 2013, 3, 486.	0.3	5
31	Invasive bladder cancer: time is of the essence. <i>Canadian Urological Association Journal</i> , 2013, 2, 109.	0.3	0
32	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 443-443.	0.8	0
33	Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. <i>Current Opinion in Urology</i> , 2009, 19, 243-246.	0.9	40
34	Recent advances in the management of superficial bladder tumors. <i>Canadian Journal of Urology</i> , 2002, 9, 1544-50.	0.0	7
35	Role of radical prostatectomy in high-risk prostate cancer. <i>Canadian Journal of Urology</i> , 2002, 9 Suppl 1, 8-13.	0.0	0
36	Lifetime occupational physical activity and incidental prostate cancer (Canada). <i>Cancer Causes and Control</i> , 2000, 11, 759-764.	0.8	41

#	ARTICLE	IF	CITATIONS
37	Dietary fat and prostate cancer survival. <i>Cancer Causes and Control</i> , 1999, 10, 245-251.	0.8	93
38	Dietary energy and nutrients in relation to preclinical prostate cancer. <i>Nutrition and Cancer</i> , 1997, 29, 120-126.	0.9	67